Alan is an experienced, oncology focused, biotech founder, entrepreneur and innovative leader focused on company ideation and strategic growth through capital raises, non-dilutive collaborative partnerships and value enhancing asset acquisitions. A mission ‘driven’, patient-centric leader focused on impacting patients’ lives through an unwavering commitment to build, focus and accelerate the advancement of innovative first-in-human / first-in-class therapies from concept to clinical validation.
Alan co-founded and served as President and CEO of HiberCell, a company focused on leveraging population level, multi-omic data to target the stress response pathways of dormant disseminated tumor cells with a goal of blunting stress and preventing cancer relapse. Under his leadership, HiberCell launched in 2019 with a $61 million USD, Series A and ultimately raised more than $250M USD. Prior to co-founding HiberCell, Alan held C-suite executive roles at Warp Drive Bio, Inc. (now RVMD), Synta Pharmaceuticals (now MDGL), and was a Vice President of Oncology at Eli Lilly and Company, where he advanced several drug discovery and development programs.
Prior to his career in biopharma and biotechnology, Alan served as an Assistant Professor and Adjunct Assistant Professor at Harvard Medical School, where his laboratory leveraged the intersection of structural and computational biology to drive drug discovery initiatives within the undruggable genome.
He holds a HBSc and PhD in Biochemistry from Canada’s Western University.